ClinicalTrials.Veeva

Menu

Effect of Radiofrequency on Insulin Resistence in Obese Post Menopansal Women

Cairo University (CU) logo

Cairo University (CU)

Status

Enrolling

Conditions

Insulin Resistance

Treatments

Device: radiofrquency device

Study type

Interventional

Funder types

Other

Identifiers

NCT05818293
012/003806

Details and patient eligibility

About

insulin resistance as the prime factor linking visceral obesity with adverse metabolic changes. Analysis of abdominal obesity by imaging studies have generally reached the conclusion that it is the excess of intra-abdominal or visceral adipose tissue .Multiple environmental and genetic factors are thought to influence the manifestation of abdominal obesity. The expanded adipose tissue contributes to expose the liver to high concentrations of free fatty acids (FFA), impairing several hepatic metabolic processes leading to hyperinsulinemia .On the other side, there is an increase in the secretion of different adipokines, such as interleukin IL-6 and tumor necrosis factor-α (TNF-α), which also contributes to the insulin-resistant state .

So, RF technology deployed by Vanquish uses oscillating electrical current forcing collisions between charged molecules and ions, which are then transformed into heat. Since fat biophysical characteristics behave like an insulator capable of polarization, it absorbs the high RF-related heat release from the RF applicator driving specific fat necrosis and consequent lipolysis. Patients lay underneath the device while the focused-field radiofrequency heats up the underlying .

Full description

The eligible participants will be divided into two equal groups included fifty two post-menopausal women. They will be selected randomly from El kalil Ebrahem hospital in Hadaek El Maadi.

Each group will be twenty six women. Group (A) (study group) will receive radiofrequency, medical standard care for insulin resistance and regular diet habits. This group will receive 30 minutes on the abdominal area by radiofrequency, twice per week. The treatment procedure consists of placing the emitting panel over abdomen and flanks close to the skin using a spacer which standardizes distance between the panel and the body surface.

Once it is in supine position, with a pillow under their heads and with their knees in flexion. Initially, the abdominal region of each participant was divided into two equal parts- right and left-with the line Alba as reference.

Group (B) (control group) will receive regular diet habits only.

Enrollment

52 estimated patients

Sex

Female

Ages

48 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • • All participants post-menopausal from at least 3 years.

    • All participants' ages will be ranged from 48-60 years old.
    • All participants BMI will exceed 30 kg/m2.
    • All participants waist hip ratio will be equal or more than 0, 89.

Exclusion criteria

  • • Surgical liposuction within the last 12 months.

    • Untreated hypo- or hyperthyroidism.
    • Uncontrolled liver, kidney or cardiovascular disease or diabetes.
    • Implanted pacemaker or metal implant.
    • History of thrombophlebitis, any hematological disease.
    • No past or present neurological and musculoskeletal disorders that will have affected health condition.
    • No smoking and drinking habits.
    • No psychological problems.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

52 participants in 2 patient groups

study group -control group
Experimental group
Description:
Group (A) (study group) will receive radiofrequency, medical standard care for insulin resistance and regular diet habits.
Treatment:
Device: radiofrquency device
control group
No Intervention group
Description:
Group (B) (control group) will receive regular diet habits only.

Trial contacts and locations

1

Loading...

Central trial contact

Shymaa M Mohammed, MSc; Dalia D Awad, PHD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems